Eris Lifesciences Reports Record FY26 Profit of ₹647.51 Cr, Declares ₹7.21 Dividend

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
Eris Lifesciences Reports Record FY26 Profit of ₹647.51 Cr, Declares ₹7.21 Dividend
Overview

Eris Lifesciences announced solid audited results for the fiscal year 2026, reporting a consolidated net profit of ₹647.51 crore on revenue of ₹3,129.42 crore. The company also declared an interim dividend of ₹7.21 per share and finalized the acquisition of a branded probiotics business.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Eris Lifesciences Reports Strong FY26 Profit and Declares Dividend

Eris Lifesciences announced its audited financial results for the fiscal year ending March 31, 2026. The company posted a consolidated revenue from operations of ₹3,129.42 crore and a consolidated net profit of ₹647.51 crore.

On a standalone basis, revenue reached ₹1,821.74 crore with a net profit of ₹244.05 crore. The Board also declared an interim dividend of ₹7.21 per share.

Strategic Growth and Shareholder Returns

This announcement provides shareholders with a clear view of the company's financial performance for the full fiscal year. The declaration of an interim dividend offers a direct return on investment, while the completed acquisitions signal strategic growth initiatives.

Recent Acquisitions

In the past year, Eris Lifesciences has been active in strategic expansion. The acquisition of the Branded Probiotics Business for ₹50 crore was finalized on March 31, 2026. Additionally, the company acquired the remaining shares in Swiss Parenteral Limited, making it a wholly-owned subsidiary as of January 16, 2026.

Future Outlook

Shareholders can expect the interim dividend of ₹7.21 per share, with payment scheduled by June 19, 2026. The integration of the acquired probiotics business is anticipated to drive future growth and broaden the company's market presence.

Auditor's Opinion

The auditor's report indicated an unmodified opinion, signifying no significant concerns from the auditors regarding the financial statements.

Key Financials and Dates

  • Consolidated Revenue (FY26): ₹3,129.42 crore
  • Consolidated Net Profit (FY26): ₹647.51 crore
  • Standalone Revenue (FY26): ₹1,821.74 crore
  • Standalone Net Profit (FY26): ₹244.05 crore
  • Interim Dividend: ₹7.21 per share
  • Record Date for Dividend: May 29, 2026
  • Dividend Payment Deadline: June 19, 2026
  • Branded Probiotics Business Acquisition: ₹50 crore, completed March 31, 2026

Investor Focus

Investors will be watching the dividend payout and the performance and integration of the newly acquired Branded Probiotics Business.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.